This article is more than 5 years old. Information may no longer be current.
Chemoreduction with cyclophosphamide controls retinoblastoma progression
Click Here to Manage Email Alerts
Chemoreduction with cyclophosphamide controlled progression of retinoblastoma while preventing the need for enucleation and external beam radiotherapy, a study found.
The retrospective study included 56 eyes of 40 patients with retinoblastoma who underwent six cycles of intravenous cyclophosphamide, vincristine, etoposide and carboplatin. Cycles were every 21 days, and mean follow-up was 101 months.
After all patients were evaluated for age at diagnosis, race, hereditary background and tumor laterality, tumors were classified by the International Classification of Retinoblastoma (ICRB).
The authors reported that 42 eyes (75%) achieved success with primary chemotherapy. ICRB classification was associated with therapy success and visual acuity at age 6 years. There was no relation between the ICRB classification and relapse occurrence.
Disclosure: The authors have no relevant financial disclosures.
Click Here to Manage Email Alerts